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ABSTRACT 
 
 Lyophilization has become a more acceptable approach in developing potentially 
unstable chemical entities.  For the purposes of this research, diclofenac, a very stable small 
molecule was chosen as the model.  The goal of this research was two fold.  First, different salts 
of diclofenac were prepared and characterized.  The characterizations of the diclofenac salts 
included appearance, crystalline characteristics, melting point, DSC, TGA, solubility in water 
and different pH buffers, and assay by High Performance Liquid Chromatography (HPLC).  
Secondly, the salts were lyophilized to determine if the salts cation affected the physical 
characteristics of the lyophilization cake.  Comparisons were be made between salts with 
monovalent cations versus divalent and trivalent cations and different sizes of cations.  The 
resulting lyophilized cakes were analytically compared as to the lyophilization cake’s 
appearance, reconstitution time, color and clarity of solution, percent moisture in the vial (Karl 
Fischer analysis) and assay by UV.  This research demonstrated that the different salts of 
diclofenac do have an effect on the final lyophilization cake.  The lyophilization cake 
appearance, reconstitution time, percent moisture and primary drying time were all affected by 
the different salts of diclofenac.   
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Introduction 
 
 Lyophilization, commonly known as freeze drying, is dehydration or the removal of 
water.  Lyophilization was first extensively used in the pharmaceutical industry during World 
War II to preserve blood plasma.  Plasma was spoiling due to the amount of time it took to ship 
to the battlefield.  Lyophilization provided a preservation mechanism.  Lyophilization has been 
developed as a preservation technique for products such as proteins, to highly oxidation sensitive 
products, and flowers (FTS, 1991).  Lyophilized products must meet certain criteria in order to 
be considered successful.  The criteria include, but are not limited to, appearance, reconstitution 
time, stability, and maintenance of the physical characteristics of the original substance (Bedu-
Addo, 2004).  The appearance of the cake must be aesthetically pleasing.  For a pharmaceutical 
lyophilized product, the cake cannot appear to be deformed, melted, or not “elegant”.  The 
reconstitution time must be within acceptable time limits.  A lyophilized product that requires 
extensive mixing or an extended reconstitution time is not considered acceptable.  One of the 
main goals of lyophilization is to improve the stability of the product.  If the stability is less than 
or equal to the original material, then the cost and time required to lyophilize do not make 
economic or scientific sense.  In terms of maintaining the physical characteristics of the original 
material, if the material undergoes changes that affect the inherent efficacy or in vitro 
mechanisms of the material then lyophilization of the product does not make pharmaceutical 
sense.  Elegance of the cake can be defined as a cake that has not collapsed (Costantino, 2004).  
Elegance also includes subjective observations about cake structure, texture, and color.  If the 
cake is not elegant, reformulation of the product might be necessary. 
 Lyophilization has become a more acceptable approach in developing potentially 
unstable chemical entities.  It allows the product to be protected from oxidation from a solvent 
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system and headspace in the vial.  Lyophilization also moves the material in question from the 
liquid state to the solid state where it is likely to be stable for a longer term (Constantino, 2004).   
 The lyophilization process takes place through three basic steps, freezing, primary drying, 
and secondary drying.  These steps are summarized in the following paragraphs. 
 The freezing step converts the material from liquid to solid state.  The freezing step is 
important because it can affect the outcome of the final product (Beaty, 2007).   The freezing rate 
of the sample solution can lead to a more optimized lyophilization cycle.  Generally, the faster 
the solution freezes, the smaller the crystals, while the slower the solution freezes, the larger the 
crystals (Beaty, 2007).  Crystal size can have a significant affect on how a product will 
lyophilize. Drying time can be increased if the small crystal size impedes the sublimation of the 
solvent out of the matrix (FTS, 1991).  
 Primary drying is the removal of free ice from the system by sublimation (FTS, 1991.)  
The sublimation of the ice is driven by a pressure difference between the vapor pressure of the 
water and the pressure of the condenser.  This difference can be directly calculated by obtaining 
the vapor pressure of the water at a specific temperature from standardized tables (Weast, 1987) 
and subtracting the pressure of the condenser (FTS, 1991).   
 Secondary drying is the removal of adhered or bound water to the surface of the cake 
matrix.  Removal of this water involves increasing the temperature of the product to provide the 
necessary energy to remove the water.  Secondary drying takes place after the temperature of the 
product reaches 0°C (FTS, 1991).  
 Considering the phase diagram of water (Encarta, 2006), see Figure 1, the aqueous 
sample solution goes from the liquid phase to the solid phase during the freezing step.  To 
remove the “solid” water by sublimation, two actions must take place; there must be a decrease 
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in pressure around the solid phase and the temperature of the solid phase must be increased until 
the ice sublimes. In a lyophilization chamber the pressure around the system is lowered using a 
vacuum pump and the temperature of the shelf in the lyophilizer is increased to provide the 
necessary temperature increase.  After the free ice is removed from the sample, the shelf 
temperature of the lyophilizer is again increased to above 0°C.  Secondary drying takes place at 
this point.   
 During the lyophilization cycle, the sample temperatures are monitored using a 
thermocouple placed in a sample vial.   It is generally accepted that when the temperature of the 
product or lyophilization cake reaches the temperature of the shelf and then tracks the shelf 
temperature, primary drying is completed (FTS, 1991).   For example, if the product temperature 
is reading -27°C when the shelf temperature is -20°C, it would be inferred that primary drying is 
not completed and more time should be allowed.   
 The goal of this research was two fold.  First, different salts of diclofenac were prepared 
and characterized, see Appendix D for salt structures.  The characterizations of the diclofenac 
salts included appearance, presence of crystalline structure, melting point, Differential Scanning 
Calorimetry (DSC), Thermogravimetric Analysis (TGA), solubility in water at different pH’s, 
and assay by High Performance Liquid Chromatography 
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Figure 1.  Phase Diagram of Water 
4  
(HPLC).  Secondly, the salts were lyophilized to determine if the salts cation affected the 
physical characteristics of the lyophilization cake.  Comparisons were be made between salts 
with monovalent cations versus divalent and trivalent cations and different sizes of cations.  The 
resulting lyophilized cakes were analytically compared as to the lyophilization cakes appearance, 
reconstitution time, color and clarity of solution, percent moisture in the vial (Karl Fischer 
analysis) and assay by UV. 
Experimental 
 Commercially prepared diclofenac salts were obtained through AAIPharma stocks and 
used throughout the research.  Sodium diclofenac is the sodium salt of diclofenac.  The sodium 
diclofenac, Lot 269/1 was manufactured by Secifarma.  The potassium diclofenac, Lot 
DCPU003, was manufactured by Yung Zip Chemical Inc., Co.  The first experiment was to 
prepare the free acid for use in possible synthetic routes to other salts of diclofenac.  Sodium 
diclofenac was dissolved in water at a concentration of 7 mg/mL.  When the sodium diclofenac 
was completely dissolved, it was titrated with an equal molar amount of hydrochloric acid.  This 
solution was allowed to stir using a magnetic stir bar and plate for 10 minutes.  Because the 
diclofenac free acid was not soluble in water, it immediately precipated out of solution 
(Khazaeinia, 2003).  The free acid of diclofenac was a suspension in water while the resulting 
sodium and chloride ions remained in solution.  The mixture was filtered using 0.45µm filter 
paper and a vacuum apparatus.  The filtrate was washed with dilute HCl (0.001 N) and excess 
amounts of water to remove any excess sodium chloride and un-reacted sodium diclofenac.  The 
powder was allowed to dry under a hood, collected and stored in a clear glass vial.  The 
solubility of the free acid in methylene chloride was shown to be greater than 5 mg/mL. 
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Ammonia Diclofenac (NH4D) 
 The preparation of NH4D was done by reacting diclofenac free acid with ammonia.  The 
reaction was completed by the ammonia deprotonating the free acid and allowing the positively 
charged ammonia group to form the salt complex.  To aid in the dissolution of the free acid, the 
final concentration of the methylene chloride solution was 4.1 mg/mL.  The free acid was 
dissolved into methylene chloride resulting in 1.4 X 10-2 moles per liter of diclofenac. Ten 
milliliters of a 1.0 N solution of ammonium hydroxide was slowly titrated into the solution using 
a class A pipette.  The solution was mixed using a stir bar and stir plate.  The solution turned to a 
milky white suspension within 30 seconds.  The suspension was mixed for 10 minutes to allow 
for the reaction to go to completion.  The suspension was transferred to a graduated cylinder and 
the water layer was removed using a disposable pipette.  The suspension was transferred to petri 
dishes and placed in a fume hood.  The methylene chloride was allowed to evaporate and the 
ammonium diclofenac was collected. 
 Tetrabutyl ammonium diclofenac was prepared and used in several lyophilization cycles.  
The salt was prepared by combining equal portions of diclofenac free acid with 0.4 M tetrabutyl 
ammonium hydroxide in water.  The reactants were placed in a scintillation vial and mixed 
overnight using a stir bar and magnetic stir plate.  It was predicted the diclofenac salt would be 
formed and water would be the only byproduct.   
Metal Stock Solution Preparation 
 Several metal stock solutions were prepared to synthesize the different diclofenac salts 
for this research.  In most cases, 1 molar stock solutions were prepared, however in the zinc 
solution, due to limited material, a 0.34 M solution was prepared.  These solutions were prepared 
volumetrically in the laboratory and used throughout the research. 
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 Magnesium Sulfate 
 The MgSO4 (formula weight 120.4 g/mole), used in the preparation of the stock solution, 
was sourced from Sigma, lot 50K0248.  A one molar solution was prepared by dissolving 12.0 g 
of MgSO4 into 100 mL volumetric flask containing approximately 80 mL of Milli-Q water (in-
house deionized water).  The solution was mixed until the resulting solution was clear and 
colorless.  The solution was filled to volume and mixed well. 
 Aluminum Chloride 
 The AlCl3 hexahydrate (formula weight 241.43), used in the preparation of the stock 
solution, was sourced from Fisher, lot 028520.  A one molar solution was prepared by dissolving 
24.1 g of AlCl3 into 100 mL volumetric flask containing approximately 80 mL of Milli-Q water.  
The solution was mixed until the resulting solution was clear and colorless.  The solution was 
filled to volume and mixed well. 
 Zinc Sulfate 
 The ZnSO4 heptahydrate (formula weight 287.5), used in the preparation of the stock 
solution, was sourced from Sigma, lot 128H14291.  A 0.34 molar solution was prepared by 
dissolving 9.7 g of ZnSO4 into 100 mL volumetric flask containing approximately 80 mL of 
Milli-Q water.  The solution was mixed until the resulting solution was clear and colorless.  The 
solution was filled to volume and mixed well. 
 Lead Nitrate 
 The Pb(NO3)2 (formula weight 331.2), used in the preparation of the stock solution, was 
sourced from Aldrich, lot 11113TU.  A one molar solution was prepared by dissolving 33.1 g of 
Pb(NO3)2  into 100 mL volumetric flask containing approximately 80 mL of Milli-Q water.  The 
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solution was mixed until the resulting solution was clear and colorless.  The solution was filled 
to volume and mixed well 
 Copper Sulfate 
 The CuSO4 (formula weight 249.7), used in the preparation of the stock solution, was 
sourced from Sigma, lot 4OK3704.  A one molar solution was prepared by dissolving 24.9 g of 
CuSO4 into 100 mL volumetric flask containing approximately 80 mL of Milli-Q water.  The 
solution was mixed until the resulting solution was clear and royal blue.  The solution was filled 
to volume and mixed well. 
Metal Complex Preparation 
 The magnesium, zinc, copper, lead, and aluminum salts of diclofenac were prepared by 
combining a metal cation with solutions of sodium diclofenac.  Because the magnesium, 
aluminum, zinc, copper and lead salts of diclofenac have limited solubility in water, they form a 
precipitate and fall out of solution.  The salts were then collected and characterized. 
 A stock solution of 0.044 molar sodium diclofenac was prepared by dissolving 25.0 
grams of sodium diclofenac in 1.8 liters of Milli-Q water. This solution was divided into sub lots 
that would be used to prepare the metal salts of diclofenac.  Sodium diclofenac has a ratio of 1:1 
between the sodium ion and the diclofenac ion.  Using this information, the correct molar 
concentration of metal salt solution was calculated so that when titrated it could be expected that 
all of the diclofenac would be reacted to the intended metal salt.  The amount of metal solutions 
used to titrate the diclofenac solution was calculated using Equation 1. The concentration of the 
lead and magnesium metal 
solutions was one molar.  The concentration of the sodium diclofenac solution was 0.044M, 
therefore the molar amount of the divalent metals needed to titrate the diclofenac solution was 
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0.022M.  The calculated amount of metal solution used to titrate the solution was 8.8 mL.  9 mL 
of solution was added to provide an excess of the metal.  The concentration of the zinc metal 
solution was 0.34 M, which required a titration volume of 25.9 mL for the correct molar 
equivalent ratio.  To provide an excess, the solution was titrated with 27 mL of zinc metal 
solution, see Table 1 for the molar equivalents used in the salts preparation.  The concentration 
of the aluminum salt solution was one molar.  Due to aluminum being a trivalent metal, 0.015 
moles of metal were needed to react all of the diclofenac in solution.  7 mL of solution were used 
to titrate the diclofenac.   
 The 400 mL aliquot of the sodium diclofenac in solution was stirred continuously using a 
stir bar and stir plate.  The metal solution was slowly titrated into the diclofenac solution using a 
class A pipette.  A white precipitate was immediately visible in the beaker.  The suspension was 
allowed to stir for an additional ten minutes.  The suspended solids were collected on filter paper 
using 0.45µm filter paper and vacuum filtration.  The filter paper and collected solids were 
resuspended using Milli-Q water to “wash” the solids.  The filter paper was then placed in a 
40°C oven and dried overnight.  This procedure was acceptable except for the lead diclofenac 
system, which passed through the filter paper.  Two alternatives for collecting the lead diclofenac 
were explored.  First, 
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Equation 1.  Molar Equivalent Calculation 
     
V1C1 = V2C2
 
 
V1 = Initial volume 
C1 = Initial concentration 
V2 = Final volume 
C2 = Final concentration 
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2Na+ + 2Diclofenac - + Mg 2+ + SO42- → MgD2 ↓ + Na2SO4
3Na+ + 3Diclofenac - + Al3+ + 3Cl- → AlD3 ↓ + 3NaCl 
2Na+ + 2Diclofenac - + Zn2+ + SO42- → ZnD2 ↓ + Na2SO4
2Na+ + 2Diclofenac - + Pb2+ + 2NO3- → PbD2 ↓ + 2NaNO3 
2Na+ + 2Diclofenac - + Cu2+ + 2NO3- → CuD2 ↓ + 2NaNO3 
 
Figure 2.  Reactions of the Diclofenac Salts Prepared 
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Table 1.  Molar Ratios for Diclofenac Salt Preparation 
 
Cation 
Molar Ratio  
(Diclofenac to Metal) 
Theoretical 
Molar Ratio 
(Diclofenac to Metal) 
Used 
Magensium 2 : 1 2.05 : 1 
Copper 2 : 1 2.05 : 1 
Zinc 2 : 1 2.08 : 1 
Lead 2 : 1 2.05 : 1 
Aluminum 3 : 1 3.5 : 1 
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an aliquot of the lead diclofenac suspension was placed in a centrifuge tube.  The sample was 
centrifuged at 3000 rotations per minute (RPM) for 30 minutes and the supernatant was poured 
off and the solids collected.  The solids were dried in a 40°C oven overnight.  The second 
approach was to filter an aliquot of the lead diclofenac system using a  
0.22 µm filter and collect the solids.  The centrifuge alternative was more effective and was used 
to process the lead diclofenac. Once the solids had dried, they were stored in amber glass bottles 
with black plastic tops.   
 Once all of the salts were prepared, they were evaluated visually for appearance, color, 
and crystallinity using an Olympus Microscope.  Salt characterization included purity by HPLC 
analysis, evaluation of crystallinity, melting point, thermogravimetric analysis (TGA), 
differential calometric scanning (DSC), solubility in water and pH 4, 7, 8, and 10 buffers. 
Appearance 
 
 The synthesized diclofenac salts were evaluated visually using an Olympus BH2 
Microscope.  The appearance, color, size and crystallinity of each powder were established.  
Slides were prepared using standard techniques with Cargille non-drying Immersion Oil for 
microscopy, Type A, lot 101376.  Each diclofenac salt was assessed at 400X under normal light 
and crossed polarized light.  Under normal light, the slide was inspected for particle size and 
quality.  Each diclofenac salt was described using common identifying terms, such as square, 
cubic, needle, agglomerates, and color.  A larger agglomerate or crystal was used to assess if the 
particulate showed birefringent light under the crossed polarized light.  This would indicate 
whether or not the sample was crystalline. 
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Sample Purity 
 Sample purity was determined using a modified high performance liquid chromatography 
method in use at AAIPharma.  The method was currently being used to test sodium diclofenac 
content in tablets.  The method was modified so that the standard ratio was correct for the 
reconstitution of the lyophilized samples.  The mobile phase was a combination of phosphate 
buffer and organic solvents, see Table 2 for mobile phase ratios.  The buffer was prepared by 
dissolving 10.2 g of potassium phosphate into 1500 mL of water and then adjusting the pH to 3.0 
using concentrated phosphoric acid.  The final pH of the solution was 3.08.  This buffer was 
mixed with acetonitrile and methanol; this solution was the mobile phase for the HPLC run.  The 
diclofenac standard was prepared by dissolving 18.57 mg of sodium diclofenac in 250 mL of 
mobile phase.  The purity of the sodium diclofenac being used for the standard preparation was 
assumed to be 100%.   
 The samples were injected on a Hewlett Packard® HP1100 high performance liquid 
chromatogram using an Altech Inertisil® ODS-2 column, 15 cm in length with an internal 
diameter of 4.6 mm and a 5 µm packing size.  The mobile phase flow rate was 1.2 mL/minutes at 
ambient temperature.  The injection volume was 10µL and the UV detector was set to 250 nm.  
The data acquisition system used was Millenium 32®, Version 4.0.  A series of three standards 
were injected to establish system suitability.   
Ksp Evaluation   
 The solubility product, Ksp, was determined by placing an excess amount of the 
diclofenac salt into a 10 mL clear glass vial and adding 5.0 mL of Milli-Q water.  A stir bar was 
placed in the vial and the vial was sealed.  The vials were stirred using a magnetic stir plate for a 
minimum of 48 hours.  The resulting solution was filtered using a 0.45 µm Nylon filter and 
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collected in a glass test tube.  The filtrate was analyzed by UV at 278 nm for amount of drug 
dissolved in the water (Pfeiffer, 1998).  Using the calculated amount of diclofenac in the water 
(mg/mL), the Ksp of each salt was calculated.  The standard for the Ksp testing was prepared by 
dissolving 26.01 mg of sodium diclofenac in 25 mL of water.  The 1mg/mL solution was then 
diluted to a working concentration of 0.01 mg/mL.  Using this standard, system suitability was 
determined by reading the standard and comparing the absorbance to previous runs and 
comparing multiple runs of the same standard.  The samples were then diluted to appropriate 
concentrations and the samples were read.  The mg/mL of diclofenac in solution was calculated 
and used to calculate total mg of diclofenac dissolved, which was then used to calculate the 
molarity and Ksp of each salt.   
pH Solubility of Metal Salts 
 As part of the characterization of the new diclofenac salts, the solubility was determined 
in pH 4.0, 7.0, 8.0, and 10.0 buffers.  Buffers were prepared using established buffer systems, see 
Table 3 for the buffer systems and actual pH.  The pH meter used was calibrated using 
commercially available buffers at pH 4.0, 7.0, and 10.0.  A series of stock solutions were 
prepared and then used to create the specific pH buffers. A 0.1M citric acid solution was 
prepared by dissolving 21.0 g of citric acid in water to 1L.  A 0.2 M dibasic sodium phosphate 
solution was prepared by dissolving 28.4 g of the salt in water to 1L.  The 0.2 M monobasic 
sodium phosphate solution was prepared by dissolving 27.6 g of salt in water to 1L.  A 0.2 M 
sodium hydroxide solution was prepared by dissolving 8.0 g of sodium hydroxide pellets in 
water to 1L.  A boric acid / 
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Table 2.  Components of HPLC Mobile Phase Preparation 
 
Component Milliliters 
Phosphate Buffer pH 3.0 450 
Methanol 250 
Acetonitrile 300 
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Equation 2.  Example Ksp Equations 
 
Sodium Diclofenac (s)  Na+ (aq) + Diclofenac – (aq) 
 = [NaKsp +] [Diclofenac-] 
Magnesium Diclofenac (s) Mg 2+ (aq) + 2Diclofenac- (aq) 
 = [MgKsp 2+] [Diclofenac-]2
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Table 3.  pH Buffer Systems Used with Measured pH  
 
pH of Buffer System  
to be Prepared 
Buffer System Used 
Measured pH of  
Buffer System 
Buffers Ionic 
Strength 
4 Citric Acid 4.01 NA 
7 Sodium Phosphate 6.96 0.22 
8 Sodium Phosphate 7.99 0.64 
10 Sodium Hydroxide 9.84 0.09 
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potassium chloride solution was prepared by dissolving 12.4 g of boric acid and 14.9 g of 
potassium chloride in water to 1L (Dawson, 1978).   
 The pH 4 buffer was prepared by combining 61.45 mL of the citric acid solution with 
38.55 mL of the dibasic sodium phosphate solution.  The dilutions were completed  
using class A pipettes and an Ependorf pipette.  The resulting solution was mixed well and the 
pH of the solution was 4.01.   
 The pH 7 buffer was prepared by combining 30.5 mL of 0.2M dibasic sodium phosphate 
solution and 19.5 mL of monobasic sodium phosphate and then diluting the solution to 100 mL 
with water.  The solution was mixed thoroughly and the resulting pH was 6.96.   
 The pH 8 buffer was prepared by combining 47.35 mL of 0.2M dibasic sodium phosphate 
solution and 2.65 mL of monobasic sodium phosphate and then diluting the solution to 100 mL 
with water.  The solution was mixed thoroughly and the resulting pH was 7.99.   
 The pH 10 buffer was prepared using 43.7 mL of the 0.2M sodium hydroxide solution 
and 50 mL of the boric acid/potassium chloride solution.  The solution was mixed well with a 
resulting pH of 9.84. 
 Samples of each diclofenac salts were prepared by adding an excess amount of salt to a 
vial containing 10 mL of the appropriate pH buffer.  The vials were labeled and sealed.  The 
vials were then placed on a sample nutator and mixed by rocking back and forth for a minimum 
of 24 hours.  The salts did not wet well and shaking the vials by hand was required to wet all of 
the diclofenac salt in the vial.   
 The final solutions were removed from mixing and filtered using syringes and 25 mm 
0.45µm nylon syringe filters.  This filter was chosen because AAIPharma had shown that these 
filters do not retain diclofenac during filtration (Pfeiffer, 1998).  A small amount of the filtrate 
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was used to saturate the filter (approximately 0.5 mL) and the rest was collected in glass test 
tubes to be analyzed by UV spectrometry for diclofenac at wavelength 278 nm.  The analysis 
was done by comparing absorbance readings of the samples to the absorbance of a 0.01 mg/mL 
standard that was prepared in the laboratory.  The standard was prepared by dissolving 26.18 mg 
of sodium diclofenac into 25 mL of water.  The solution was then diluted to the working 
concentration with the appropriate pH buffer.  The working concentration of each salt in each pH 
buffer was established and the absorbance recorded.  Using this absorbance, along with the 
dilution information, the mg/mL dissolved of each salt was calculated.   
X-Ray Diffraction  
 Samples of ammonium, magnesium, lead, and aluminum diclofenac samples were run 
using Siemens Diffraktometer using Materials Data Incorporated Data Scan® 4 with Materials 
Data Incorporated Jade®, Version 7 printing software. The experiment was carried out by 
affixing a small amount of sample to the quartz zero-background sample plate and mounted in 
the instrument.  The sample was then scanned from 2° to 40° at 0.05° intervals with a scan rate 
2.4°/min and the refractance of the x-rays was measured (Stowell, 2002).   
Melting Point Determination  
 The melting point of each salt was determined in the lab using a 9100 Electrothermal 
melting point apparatus.  The melting point of each salt was estimated using the fastest ramp rate 
of the melting point apparatus.  Once an estimate for each of the salts melting point was 
determined, the temperature ramp rate was slowed and a more specific melting point was 
determined.  This work was compared to the evaluation of the salts by Differential Scanning 
Calorimetry.  
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TGA
 Thermogravimetric analysis (TGA) of each salt was carried out in the physical 
characterization laboratory at AAIPharma.  The TGA samples were analyzed using a Seiko® 
Instruments TG/DTA 220 with the Seiko software package, version 6.0.  Individual samples of 
approximately 10 mg were analyzed from 30°C to 350°C with a ramp rate of 10°C per minute. 
The analysis of the TGA chromatograms was used to determine the amount of solvent loss from 
the salt complex (Mettler, 2001).   
DSC 
 Differential Scanning calorimetry analysis of the diclofenac salts provided information on 
the possible formation of hydrates of the samples.  The samples were analyzed using a Mettler 
Toledo® DSC821e instrument using STARe® software, version 6.01.  The samples were heated 
from 30°C to 350°C with a ramp rate of 10.0°C per minute. The DSC provided chromatograms 
of the salts melting and recrystallizing characteristics (Mettler, 2001).
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Equation 3.  Calculation of mg/mL Diclofenac in pH Buffer Solubility Study 
 
SampleofDilution
StdofDilution
mLStdofVol
PuritymgwtStd
StdofArea
SampleofAreaA ×××=
)(
)(
 
StdinDofMole
SampleinMoleofD
NaDmole
NaDmgDSampleofmole
mgSampleofwtFormulaB ××=
1
317000
1
1
)(  
A * B = mg/mL Diclofenac in pH Buffer System 
 
Area of Sample = Area of sample 
Area of Std = Area of standard 
Std wt = weight of standard in mg 
Vol of Std = Volume of standard in mL 
Dilution of Std = Dilution of standard in mL/mL 
Dilution of Sample = Dilution of sample in mL/mL 
Formula wt of Sample = Formula weight of sample diclofenac in mg 
1 mole of Sample D = 1 mole of Sample Diclofenac 
317000 mg NaD = Formula weight of sodium diclofenac in mg 
Mole of D in Sample = Moles of diclofenac in sample preparation 
Mole of D in Std = Moles of diclofenac in standard preparation 
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Crystal Analysis 
 A series of experiments were conducted with the intention of growing large single 
crystals that could be used for crystal analysis and photographic analysis (Boyle, 2004).  Seven 
different solvent systems were chosen based on the above article and standard  
universal solvents for growing crystals.  The solvents were prepared in bulk and individual 
samples were prepared by charging a small amount of diclofenac salt, approximately 5 mg, into a 
5 mL clear glass vial.  Two to three mL of solvent were charged to the vial and the diclofenac 
salt was dissolved in the solvent system.  The vials were covered with parafilm and two small 
holes were pierced in the parafilm.    
Lyophilization cycle experiments 
 The lyophilizer used for this research was an FTS Dura-Stop µp shelf system with a 
Dura-Dry µp condenser located in the Formulation Development laboratory of AAIPharma.  The 
Dura-Stop µm shelf system had a 4.5 square foot of dryer with three separate shelves.  The Dura-
Dry µp condenser had a capacity of five liters at a temperature of -80°C.  The vacuum pump had 
the capability of achieving a vacuum of approximately 25 mT. The data acquisition system for 
the lyophilizer was Lyoware® version 2.2.  The software had the capability to program the 
system with different temperature ramp rates, temperature hold times, and operating pressures as 
needed for this project.  The software could then provide numerical data of the lyophilization 
cycle along with a graphical representation of the data.  These graphs provided an excellent  
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Table 4.  Solvent Systems Used in the Crystal Growing Experiments 
 
Solvents 
Acetonitrile 
Ethanol 
Methanol 
Acetone 
50:50 Ethanol : Water 
50:50 Methanol : Water 
50:50 Acetonitrile : Water 
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overview of the cycle and were used extensively in evaluating the effectiveness of the 
lyophilization cycle.   
 Initial studies of sodium diclofenac and potassium diclofenac were prepared at 10 mg/mL 
in water with 2% w/v mannitol.  The mannitol was used as a bulking agent (Kibbe, 2000).  The 
bulking agent was used to provide mass for the formation of the lyophilization cake.  The cake 
provides a measurable entity for comparison of the different diclofenac salts.  The factors used in 
the comparisons included cake appearance, reconstitution time, and retained moisture.  The 
appearance was a visual description of the lyophilization cake characteristics including texture, 
color and height. The samples were then analyzed for reconstitution time, clarity of solution, 
retained moisture by Karl Fischer, and assayed by UV analysis.  The reconstitution time was 
determined by the time it took for the cake to completely dissolve leaving a clear solution.  The 
definition for clarity of solution was found in the United States Pharmacopeia (USP 28, 2005).  
For a sample to meet the USP definition it must meet the following requirements. One, “the solid 
dissolves completely, leaving no visible residue as undissolved matter” and two, “The 
constituted solution is not significantly less clear than an equal volume of the diluent or of 
purified water contained in a similar vessel and examined similarly” (USP 28, 2005).   The 
retained moisture was determined by Karl Fischer testing.  The Karl Fischer testing was 
completed using a Brinkmann, Metrohm 701 KF Titrono Karl Fisher apparatus, Hydranol 
Composite -2 as the titrant and methanol.  The vials were reconstituted with a known volume of 
methanol and mixed well.  The KF apparatus was calibrated using approximately 10 µL of water 
and blanked with methanol that had been dried with molecular sieves.  Samples were then 
reconstituted with the dried methanol.  
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 The samples were mixed for approximately 30 seconds and then allowed to settle on the 
bench.  A portion of the sample/methanol mixture was then injected into the KF apparatus and 
titrated with the Hydranol composite-2 solution.  For most pharmaceutical lyophilized 
preparations, the percent water content for the lyophilized cake should be less than 3% (Nakhla, 
2005).  The percent moisture per vial was calculated using Equation 4. 
 Initially, water would be the solvent system for all of the formulations in the study.  This 
proved impossible because most of the salts used in this study did not dissolve to the proposed 
concentration in water.  Because the solvent must sublime in order to be a feasible lyophilization 
solvent and the study required currently available pharmaceutically acceptable solvents, only 
ethanol and tert-butyl alcohol were used along with water.  Initial lyophilization cycle 
experiments were carried out using 20 mL  
type 1 clear glass vials with 20 mm finish.  The stoppers were West 4432/50 grey butyl rubber 
lyophilization stoppers.   
Results 
Salt Characterization Appearance Results 
 The ammonium diclofenac (NH4D) was a white fine powder.  The particles were non-
descript under normal light conditions.  The particle size ranged from fines to greater than 200 
µm.  The samples did produce birefringence when exposed to crossed polarized light. 
 The magnesium di-diclofenac (MgD2) was a white to off white powder.  The particles 
were non-descript under normal light conditions.  The particle size ranged from fines to greater 
than 200 µm.  The samples did produce birefringence when exposed to crossed polarized light. 
26  
 
Equation 4.  Calculation for % Moisture by Karl Fischer Analysis 
 
= ( )( ) %100)(
Re)()()/(
×
×
×〉−〈×
mLVolInjectionmgwtSample
mLVolonconstitutimLVBlankmLVStdmLmgFactorKF    
 
 
KF Factor (mg/mL) = Standardization Value in mg/mL 
VStd (mL) = Volume of tritrant used for sample in mL 
VBlank (mL) = Volume of titrant used for blank in mL 
Reconstitution Vol (mL) = Reconstitution volume of sample in mL 
Sample wt (mg) = weight of sample in mg 
Injection Vol (mL) = volume of sample analyzed in mL 
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Table 5.  Lyophilization Cycle used to Evaluate 0.2% Mannitol versus 0.5% Mannitol Bulking 
Concentration 
Rate °C/min 
Final 
Temperature °C
Hold Time 
(minutes) 
Pressure MT 
2.5 -40 120 Ambient 
Evacuate the chamber 
Fore line Pressure = 135 mT 
Chamber Pressure = 185 mT 
0.6 0 120 225 
0.1 27 120 225 
0.0 27 NA 1100 
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 The zinc di-diclofenac (ZnD2) was a white granular powder with a crystalline 
appearance.  The particle size of the crystals was approximately 200 µm in size.  The crystals 
were square with a cross moving from corner to corner in the crystal.  The crystals did not show 
height in any of the slides assessed.  The samples did produce birefringence when exposed to 
crossed polarized light. 
 The lead di-diclofenac (PbD2) was a fine white powder with many agglomerates ranging 
in size from fines to greater than 200 µm.  The sample did not show any birefringence when 
viewed under crossed polarized light. 
 The aluminum tri-diclofenac (AlD3) formed a sticky white to off white mass.  The sample 
required additional drying before a slide could be prepared.  The particle size of the samples was 
very small, less than 2.0 µm in size.  The sample contained agglomerates that were larger in size. 
 The copper di-diclofenac (CuD2) formed two different substances.  The first was a light 
green powder and the second an emerald green crystal structure.  The emerald green crystals 
were observed to be approximately 200 µm in size.  The shape of the emerald green crystal was 
determined to be six sided flat cubic crystal (Crystal Shapes, 2000).  The light green powder was 
measured at approximately 80-120 µm.  Using the data from the DSC, it was determined that the 
two materials were different hydrates of the copper salt.  The light green material was a 
hexahydrate salt while the emerald green crystals were the dihydrate.   
Crystal Growth Analysis 
 Although the experiments were continued for over 6 months, no acceptable single crystal 
was formed.  Several crystal cluster groups were formed but were judged inappropriate for use in 
crystal analysis.  Only a few crystals were marginal for use and all were of the free acid form and 
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not one of the salt complexes used in this research.  Additional work in this area would be 
appropriate to continue this research. 
X ray diffraction 
 The X-ray diffraction chromatogram compared intensity in counts compared to 2-Theta 
(degrees), see Appendix E for raw data.  A chromatogram that showed sharp, high intensity 
peaks represented a compound with strong crystalline characteristics.  Zinc Diclofenac and 
copper diclofenac were not analyzed due to the crystalline structure being visually observed.  
The zinc crystal structure were square flat plates with no observable height.  The copper 
diclofenac crystals were emerald green in color, six sided cubic, and flat in shape.  The results of 
this analysis show that the ammonia diclofenac, magnesium diclofenac, and the lead diclofenac 
have some crystalline properties.  The aluminum diclofenac did not show any sharp, high 
intensity peaks.  Using this information, the aluminum diclofenac might be able to be dissolved 
and recrystallized but in its current physical state, it was not crystalline, see Table 6 for a 
summary of the results. 
HPLC Assay Results 
 This method of analysis was successful because the samples dissolved easily into the 
mobile phase using only mechanical shaking and sonication.  With a run time of only 25 
minutes, the analysis time was acceptable for routine use in the analytical laboratory.  The peak 
shape was excellent with no fronting or tailing, see Figure 3 for a chromatography example.  The 
three standards reproduced with an average of 277209.4 area counts and a relative standard 
deviation of 0.3 %.  The results of the assay for the aluminum, zinc, lead, and copper salts were 
acceptable because they were with in 90 to 110 % of the expected assay value, see Table 7.  The 
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magnesium salt result, 80.0%, was lower than expected.  Upon completion of the TGA data, a 
reason for the 80% recovery was determined.  The magnesium salt had a water content of 
approximately 20%.  The magnesium diclofenac weight percent decreased from 99.9% to 78.7% 
at 100°C.  The 80% assay result was then accounted for by hydration of the salt.                                                    
 The results for the ammonia assay were explained by the reaction of the free acid not 
going to completion.  Because the free acid was lighter in weight than the reacted ammonium, 
any “contamination” of the product from free acid diclofenac would cause the calculated purity 
to be higher than 100%.  Further investigation of the assay result demonstrated that the 
maximum difference that could be accounted for by a 100% free  
acid contamination would be 105.7%.  Published data reports that the ammonium diclofenac has 
the potential to degrade to ammonia gas and the free acid form of diclofenac (Fini, 2005).  The 
DSC data for the ammonium diclofenac supported this hypothesis.  The plot exhibited a drifting 
baseline that was accounted for by the off gassing of ammonia.  The exotherm at approximately 
100°C was attributed to a recrystallization due to loss in solvent, and the large exotherm at 
approximately 169° could be the recrystallization of the free acid form of diclofenac due the loss 
of ammonia from the system. The ammonium salt characterization was completed but due the 
potential loss of the ammonia calling into question the results, the ammonium salt was 
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Table 6.  Results of X-Ray Diffraction Scans of Diclofenac Compounds 
Compound X-Ray Scan Results 
Ammonia Diclofenac Sharp, High Intensity Peaks 
Magnesium Diclofenac Sharp, High Intensity Peaks 
Aluminum Diclofenac No Peaks Observed. 
Lead Diclofenac Sharp, High Intensity Peaks 
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Figure 3.  Example Sample Chromatography of Sodium Diclofenac 
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Table 7.   Salt Purity Results from HPLC Analysis 
 
Diclofenac Salt 
Percent Assay 
% LC 
Percent Assay (%LC) 
Corrected for % Solvent Loss 
Ammonia 111.8 NA 
Magnesium 80.0 102.0 
Aluminum 98.1 98.4 
Zinc 92.2 100.4 
Lead 95.7 96.8 
Copper 91.8 104.3 
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not used in the final lyophilization studies.  Several experiments were conducted using a 
tetrabutyl ammonium diclofenac.  However, due lack of crystal formation of the material for the 
characterization studies, the experiments were not completed.  Additional research could be 
explored using this salt 
.Melting Point DSC and TGA Results 
 
 The DSC provided scans of the salts thermal events, such as melting (Mettler, 2001). The 
analysis of the TGA chromatograms was used to determine the amount of solvent loss in the salt 
complex (Mettler, 2001).  The laboratory determined melting points closely reflected the melting 
points determined by DSC, see Table 9. TGA printouts and DSC thermograms are found in 
Appendix B and C respectively.  No additional cleanup procedures were used to prepare samples 
for either the TGA or DSC analysis.  The samples were also not dried to constant weight before 
analysis took place.  The TGA analysis established that all of the synthesized diclofenac salts 
(the sodium and potassium salts were commercially obtained) contain some solvent.  Water was 
the only solvent used during the synthesis and therefore any solvent loss was attributed to water 
loss, see Table 8 for a summary of solvent loss. 
 The TGA for sodium diclofenac showed a loss of less than 2% by weight up to 250°C.  
The DSC for sodium diclofenac was similar to published DSC thermogram (Florey, 1990).  The 
scan displayed an inflection at approximately 280°C which relates to a melt with decomposition.  
The melting point range for sodium diclofenac has been reported as 283-285°C (Florey, 1990).  
Published data was also found that contradicts the conclusions drawn by Florey.  The data 
suggests that the melt and decomposition, described by Florey, are the decomposition of 
diclofenac to form new chemical entities 
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Table 8.  Weight Loss by percent attributed to solvent loss in synthesized Diclofenac salts. 
 
 
Salt Cation Weight loss by Percent 
Sodium 0.9 
Potassium 0.0 
Magnesium 21.3 
Copper 12.0 
Zinc 8.2 
Lead 1.2 
Aluminum 0.2 
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Table 9.  Melting points determined in Laboratory using 9100 Electrothermal Melting Point 
Apparatus. 
 
Salt 
Approximate 
Melting point °C 
(Onset) 
Melting Point from 
DSC °C 
Literature Values 
°C 
Diclofenac Free Acid  NA NA 
156-158 
(Budavari, 1996) 
Sodium Diclofenac 284 285 
283-285 
(Budavari, 1996) 
Potassium Diclofenac 290 285 
278-283 
(Yung, 2002) 
Ammonium 
Diclofenac 
Not completed 166 
Approximately 170 
(Fini, 2005) 
Magnesium 
Diclofenac 
257 275 
291 
(Fini, 2005) 
Zinc Diclofenac 255 250 NA 
Copper Diclofenac 183 219 NA 
Lead Diclofenac 189 180 NA 
Aluminum Diclofenac 
Melted with 
Decomposed at 180
175 NA 
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and then degradation of the oxidation byproducts (Tudja, 2001).  The DSC spectra for the 
sodium, potassium, magnesium, zinc, lead, and aluminum salts all exhibit some inflection 
between 260 and 280°C.  These inflections could be explained by the degradation of diclofenac 
to form new chemical entities. Ammonia and copper do not indicate any inflections in the DSC 
baseline between 260 and 280°C.  Further research would be necessary to determine if the 
inflections in the DSC of the salts presented in this research directly correlate to the conclusions 
put forth by Tudja. 
 The DSC for potassium diclofenac also agreed with published DSC thermograms and the 
correlating melting points (Fini, Dec. 2001).  The material exhibits a decomposition and melt at 
approximately 278°C to 282°C.  The reported melting point range for potassium diclofenac was 
278-283°C (Yung Zip, 2002).  Using these two commercially available materials as references, 
the remaining samples were then analyzed by TGA and DSC. 
 The TGA for magnesium diclofenac confirmed the assay result of 80.0% in that the 
material lost approximately 21.2% of its weight during the analysis.  The TGA instrument also 
measures DTA or differential thermal analysis.  DTA and DSC data should correspond.  The 
DSC chromatograph displays several endotherms between 70 and 120°C.  These results indicate 
a loss in solvent.  Because of the 20 % loss in weight being attributed to loss in solvent, the 
multiple peaks would be explained by lower and higher energy bound solvent being lost.   The 
chromatogram also displays a exotherm at approximately 180°C.  This indicates a 
recrystallization of the complex into a more stable form.  There is a final endotherm and melt at 
approximately 260-275°C. 
 There are two crystalline forms of the copper diclofenac (Bob Whittle, personal 
conversation).  The first form contains approximately 9% by weight solvent.  After the loss of 
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this solvent at 100-117°C the material exhibits an exotherm at 176°C, which indicates a 
recrystallization to a more stable structure.  The material then loses an additional 3% by weight 
before the material exhibits an endotherm at 219°C which indicates a melt and degradation of the 
material.  Additional DSC experiments on the copper diclofenac were also carried out.  Scans 
were obtained showing the original temperature ramp rate to approximately 185° C and then the 
sample was cooled to 30°C before the temperature was again ramped up to 350°C.  The 
experiment demonstrated that the endotherm/solvent loss at approximately 100°C was completed 
and the recrystallization at 176°C was not degradation. 
 The DSC and TGA for zinc diclofenac correlate in that both indicate an endotherm at 
approximately 100°C, a solvent loss.  The DSC and DTA show evidence to a recrystallization at 
181°C to a new structure before a final melt and degradation at 262°C.  The DSC was also 
analyzed using the same type of ramping then cooling of the samples as the copper diclofenac.  
Again the DSC demonstrated that the solvent loss at 100°C was complete and the exotherm at 
181° was a recrystallization and not a degradation of the sample.  The TGA data indicates a total 
loss of 8 percent by weight which correlates with the assay value of 95.7%.  The DSC derived 
melting point of the zinc diclofenac was 250°C. 
 The lead diclofenac TGA data demonstrated that the material did not lose any adhered 
solvent until the temperature was in excess of 170°C.  The weight of the sample lost 
approximately 20% as the temperature increased through 300°C.  The DSC and DTA data 
indicate a strong endotherm between 170 and 220°C with several distinct peaks.  A 20% weight 
loss indicates approximately 10 water molecules were displaced.  This could account for the 
multiple peaks in the endotherm between 170 and 220°C.  The DSC and DTA also exhibit an 
exotherm followed by an endotherm between 300 and 340°.  This would indicate that the 
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material recrystallized into a more stable form and then melted.  The melting point result 
correlates to the loss in solvent at approximately 180°C and was experimentally found to be 
189°C. 
  The aluminum diclofenac original TGA data did not compare with the assay value 
obtained earlier.  The assay value, 92.2%, did not correlate to the 60% loss in weight according 
to the TGA data.  The DSC also exhibited a large endotherm at approximately 90-120°C.  The 
preparation of the material included a drying step after collection on filter paper.  The salt was 
then transferred to clear glass vial with screw top for storage.  The assay analysis was completed 
using the material after the drying step.  The TGA and DSC analysis was completed later.  The 
hypothesis was that the material was hygroscopic and had adsorbed water during the time 
between the assay and the TGA and DSC analysis.  To support this hypothesis and to acquire 
meaningful TGA and DSC data, the aluminum diclofenac was dried in an oven at 105° C for 16 
hours.  The salt was removed from the oven and allowed to cool in a desiccator.   The DSC and 
TGA analysis were reanalyzed using the dried material and the results were more in line with the 
original assay data.  The TGA exhibited a loss of approximately 0.2 percent by weight.  The 
DSC and DTA both correlate to the TG data in that there were no endotherms observed at 100°C 
which would indicate losses in solvent. Based on this data, the assay value of 92.3% LC was 
acceptable, however for future work, the aluminum diclofenac should be dried before use. 
Solubility in Water and pH Buffers 
 The Ksp values for each salt were calculated using the results from the maximum 
solubility in water experiment, see Table 12 for results.  The solubility of sodium diclofenac in 
water was determined to be 18.7 mg/mL.  The pH of the water used was approximately 6.  This 
value correlates with the result published by Kincl (Kincl, 2004).  Using the assay results 
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(mg/mL), the molarity of each solution and the Ksp of each salt was calculated.  It was evident 
by the decreasing Ksp values that the solubility of the salt decreased in water as the size of the 
cation increased.  In the pH buffers, all of the diclofenac salts exhibited no solubility at pH 4.  
The salts were diluted to the concentration of the working standard and no spectra were visible.  
To confirm this result, the stock solution was then assayed.  Again, there were no visible spectra 
observed for each of the salts.   The pH 7, 8, and 10 buffer solubility samples were collected and 
analyzed by UV spectrometry.  The results are listed in Table 10 and for sodium diclofenac, 
compare favorably with published results of solubility in pH buffered systems (Kincl, 2004).  
The differences in solubility results between water and the pH buffer systems have been reported 
to be a function of both pH and ionic strength (Kincl, 2004).  Initially, the results indicated that 
at pH 7, the solubility of the salt was dependent on its cation valence and size, however upon 
statistical evaluation revealed no significant difference (P<0.05).  Among the divalent cations, 
the solubility appeared to decrease as the size of the cation increased, but again were all 
approximately the same after the variance of the results were accounted for and no trends were 
noted (P<0.05).  It was evident that the copper cation demonstrated a slightly higher solubility 
than the other +2 cations.  A possibility for the increase in solubility of copper diclofenac could 
be that the copper diclofenac salt recovered was in two different forms which were physically 
distinct, one an emerald green crystalline matrix and also a light green structure that did not 
appear to be crystalline.  The calculation of water content from the TGA scan show one form of 
the copper salt contains six waters while the other form contains only two water molecules.   The 
emerald green crystals contained two water molecules (Bob Whittle, personal communication) as 
AAI had completed crystal structure analysis of copper di-diclofenac.  It was possible that one 
structure has a greater rate of solubility than the other salts. Lead salts are well known to be 
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minimally soluble in water.  As there was only one trivalent cation used in this research, no 
trending could be observed except that its solubility was less than that of either the single valent 
or divalent cations. The different diclofenac salts solubility increased, in almost all cases, as the 
pH of the buffer increased.  The possible trend in solubility of the salts decreasing as the cation 
ion size increase was not as distinguished at the higher pH.  The pKa of diclofenac has been 
reported as 4.0 (Florey, 1990).  The increase in solubility can be attributed to the disassociation 
of the salt at the higher pH. 
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Table 10.  Solubility of Diclofenac Complexes at pH 7, 8, and 10. 
Cation 
pH 7 Buffer 
mg/mL 
pH 8 Buffer 
mg/mL 
pH 10 Buffer 
mg/mL 
Na 1.04 4.01 4.14 
K 0.89 4.38 4.06 
NH4 0.61 1.44 1.49 
Mg 1.35 1.42 0.69 
Cu 1.60 3.49 3.01 
Zn 1.26 1.71 1.61 
Pb 1.21 1.17 0.34 
Al 0.57 0.91 1.01 
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Table 11.  Atomic Radii of Metals Used to Formulate Diclofenac Salts 
 
Cation 
Atomic Radii (Å) 
(Weast, 1986) 
Na 0.97 
K 1.33 
NH4 1.43 
Mg 0.66 
Cu 0.72 
Zn 0.74 
Pb 1.20 
Al 0.50 
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Figure 4.  Solubility of Diclofenac Complexes at pH 7 
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Figure 5.  Solubility of Diclofenac Complexes at pH 8. 
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 Figure 6.  Solubility of Diclofenac Salts at pH 10 
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Figure 7.  Comparison Graph of Solubility of Diclofenac Salts in pH 7, 8, and 10 Buffer 
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Table 12.  Solubility of Diclofenac Complexes in Water with Calculated Ksp Values 
 
Salt Solubility in Water (mg/mL) Calculated Ksp 
Na 18.7 3.45 X10
-3
K 35.0 1.08 X 10-2
NH4 0.272 7.17 X 10-10
Mg 2.18 1.79 X 10-7
Cu 0.269 2.81 X 10-10
Zn 0.470 1.55 X 10-09
Pb 0.330 3.47 X 10-10
Al 0.030 8.50 X 10-17
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Lyophilization  
 Using the metal salts prepared for this research, samples were prepared with a goal of 10 
mg of diclofenac per mL of solution.  It was determined that water could not be used for all of 
the proposed salts due to their limited solubility.  Several different solvent concentrations of 
water and ethanol and water and t-butyl alcohol were explored.  Although the solvents increased 
the concentration of the solution in most cases to the desired concentration, the lyophilization 
cycle had to be changed in order to successfully lyophilize the samples.  Several cycles were run 
in the laboratory but all resulted in poor cake formation or the cycle parameters caused the cake 
to “pop”.  Popping was caused by un-sublimed solvent melting due to increased shelf 
temperature and then boiling due to the lowered pressure.  The boiling caused the cake to 
disintegrate and pop out of the vial.  Many different experiments were carried out with very 
limited success at maintaining intact cakes.  When cakes were formed, the appearance did not 
have any common characteristics with the cakes when water was used as the solvent. 
 The goal of the research was to determine if the different salts of diclofenac would cause 
physical differences in the cake formation during lyophilization.  With several different solvent 
systems and different lyophilization cycles for each solvent, it was becoming very difficult to 
make any direct comparisons.  Therefore the target concentration of 10 mg/mL diclofenac was 
reduced to a target concentration of 0.15 mg/mL diclofenac.  This change allowed for a 
consistent aqueous solvent system and the use of the same lyophilization cycle for all salts.  A 
single solvent system using the same lyophilization cycle allowed for a direct comparison of the 
cake properties between the different salts.  Initial experiments were conducted using only 
mannitol at 0.2 and 0.5% in water as control samples.  Using the control samples, both the cycle 
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and the correct concentration of mannitol could be evaluated, see Table 5 for lyophilization 
cycle.  The control samples were prepared and filled at both the 0.2% w/v and 0.5% w/v 
concentrations.  The goal of the experiment was to obtain cake stability at lower mannitol 
concentrations.  Use of a lower concentration of mannitol, as compared to 2.0% w/v used in 
earlier experiments, allowed for subtle differences in cake properties to be more evident and not 
masked by the larger concentration of mannitol.   It was necessary to use enough mannitol so that 
the cake would stand the lyophilization process and not disintegrate into powder in the vial.  The 
0.2% w/v mannitol lyophilization cakes did not provide the cake stability needed for this 
research and was not used in further tests.  The 0.5% w/v mannitol sample did demonstrate the 
necessary cake robustness and was used for all of the subsequent lyophilization runs. 
 Lyophilization cycle development was completed over a series of lyophilization runs by 
analyzing the graphs of the shelf temperature versus the thermocouple temperature, which reads 
the temperature of the cake in a vial.  The optimum cycle would allow the thermocouple date to 
approach the shelf temperature during the primary drying portion of the lyophilization cycle.  As 
the thermocouple temperature reaches the shelf temperature, it indicates that the free ice has been 
removed.  Several lyophilization runs were completed before the initial cycle parameters were 
established.  Cycles that did not meet the minimum acceptable cake parameters resulted in cakes 
that melted back into solution.  This was caused by ice remaining in the vial and after the ice 
melted, there was enough water to re-dissolve the mannitol and diclofenac salt.  See Table 13 for 
the cycle parameters used for the samples described in this research.  After the samples from 
each lyophilization cycle were analyzed, the cycle’s primary drying and secondary drying times 
were evaluated and changed to achieve a drier and more pharmaceutically acceptable cake. 
Appendix A contains the lyophilization cycle parameters along with the graphical 
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representations and numerical printout from the five lyophilization cycles discussed in this 
research. 
 The percent moisture was determined by Karl Fischer.  There were a series of five runs 
completed once the salt concentration, mannitol concentration and cycle parameters were 
established.  The cycles were essentially the same except for primary drying time and in the last 
run the secondary drying time was also increased.   
 The appearance evaluation considered the cake height, color, and consistency.  The 
consistency would be defined as crystalline with a floss like structure similar of cotton candy.  
The color for all samples except the copper diclofenac was white.  The copper diclofenac has a 
slight green tint to the cake.  This was consistent with the color of the stock copper diclofenac 
solution.  The cakes consistency showed some variance in amount of crust and adherence to the 
vial wall between the different salt versions of diclofenac, however all the cakes displayed a 
crust on top of the cake with the body of the cake appearing to be floss like.  Due to the small 
amount of bulking agent, 0.5% mannitol, the structure of the cake was not very stable.  
Manipulation of the vial caused  
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Table 13.  Lyophilization Cycle Used for Samples Described in Research 
 
Rate °C/min 
Final 
Temperature 
°C 
Hold Time 
(hours) 
Pressure 
 mT 
Step 
Definitions 
0.2 -40 2 Ambient Freezing 
Evacuate the chamber 
Fore line Pressure = 135 mT 
Chamber Pressure = 185 mT 
0.1 -10 16 225 
Primary 
Drying 
0.1 27 12 225 
Secondary 
Drying 
0.0 27 NA 1100 Vial Sealing 
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the cake structure to fail, leaving only a fine white powder in the vial, see Table 14 for a 
summary of the cake heights. 
 Reconstitution time of the samples did not vary in the total time it took to completely 
dissolve, but there were differences in the way that the cake dissolved.  The reconstitution time 
for all samples was less than 30 seconds, see Table 15 for reconstitution times.  Cakes that 
contained a more substantial crust dissolved from the top of the cake to the bottom whereas the 
lighter, more finely divided cake would dissolve from the bottom of the vial upwards through the 
cake.  The copper and zinc lyophilization cakes had the most prominent crusts of the samples.   
This crust formation was hypothesized that it could be caused by the concentration of the 
diclofenac salt from the loss in solvent/water as the sample froze.  The diclofenac salt would 
concentrate at the top of the vial because the vial freezes from the bottom to the top. 
 All samples met the criteria for clarity of solution.  Once the sample was reconstituted, 
the samples were allowed to sit on the bench top for several minutes before being observed.  All 
samples were clear with no visible residue when compared to an equal volume of Milli-Q water.  
This was important in that the lyophilization cakes must dissolve completely to be correctly 
assayed for diclofenac content.   
 The Karl Fischer analysis was completed and the results are summarized in Table 16.  
The results demonstrate that during the earlier lyophilization runs, there were differences 
between the salts in the percent water remaining in the vial.  At 16 hours of primary drying, the 
copper salt had lowest amount of retained moisture at 2.3% and the potassium salt contained the 
highest amount of retained moisture at 4.7%.  This range of 2.4% moisture demonstrates there 
are differences in how the cakes are drying in the  
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Table 14.  Lyophilized Cake Heights 
 
 
Primary Drying Time 
Secondary Drying 
Time 
16 Hours 
12 Hours 
24 Hours 
12 Hours 
36 Hours 
12 Hours 
48 Hours 
12 Hours 
48 Hours 
24 Hours 
Cake Height (cm) 
Control 0.5 1.5 2.0 2.0 2.0 
Na 2.0 1.8 2.0 2.0 2.0 
K 2.0 1.8 1.8 2.0 2.0 
TBAD 2.0 2.0 2.0   
Mg 1.0 1.8 2.0 2.0 2.0 
Zn 1.6 1.8 1.8 2.0 2.0 
Cu 1.8 2.0 2.0 2.0 2.0 
Pb  1.8 2.0 2.0 2.0 
Al 1.0 1.8 2.0 2.0 2.0 
53  
Table 15.  Lyophilized Cake Reconstitution Time 
 
Cation 
Recon Time 
Seconds 
Control 10 
Sodium 5 
Potassium 10 
Magnesium < 5 
Zinc 20 
Copper 10 
Aluminum <5 
Tetrabutyl ammonium <2.5 
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lyophilizer.  At 24 hours of primary drying the range in moisture levels has fallen to 1.4%.  As 
the lyophilization cycle’s primary and secondary drying were extended, the percent moisture 
levels for all salts converged at approximately one percent.  For the longest primary and 
secondary drying lyophilization cycle, the range in retained moisture was 0.45%, see Figure 8 for 
a bar graph of the percent moisture levels during the five lyophilization cycles.  In terms of the 
research, it was a noteworthy discovery in that there were observable differences between the 
different salts.  However in terms of a pharmaceutical application, no lyophilization cake of a 
small molecule would be left at the higher percent moisture levels.  It was also noted that the two 
observable crystalline salts, zinc and copper, dried to a greater degree than the other samples.  
This ability to dry more quickly, even at the shorter primary drying times could be related to the 
crystalline structure of the active.  As the water is removed and the diclofenac salts and mannitol 
become solid cake, the larger crystals of the zinc and copper could be providing channels for the 
moisture to move more freely in. For development of future lyophilization cycles,  
it would be worth considering the size and molecular weight of the salt along with its physical 
structure when developing the initial conditions for a lyophilization cycle.   
 It is noted that the sample volume changed from 2 mL injected to 5 mL injected for the 
two 48 hour primary drying runs.  This change was due to the reduced amount of moisture in the 
lyophilization cake.  The additional sample size increased the accuracy of the analysis. 
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Table 16.  % Moisture by Karl Fischer for Lyophilization Cakes 
 
 
Primary Drying Time 
Secondary Drying 
Time 
16 Hours 
12 Hours 
24 Hours 
12 Hours 
36 Hours 
12 Hours 
48 Hours 
12 Hours 
48 Hours 
24 Hours 
Sample Size 2 mL 2 mL 2 mL 5 mL 5 mL 
 Percent Moisture per Vial 
Control NA 1.61 1.31 0.51 0.60 
Na 4.18 2.51 3.02 1.17 0.77 
K 4.70 2.81 3.41 0.95 0.93 
TBAD 2.85 1.96 1.44   
Mg 4.45 2.19 1.17 0.69 0.78 
Zn 2.97 1.69 0.2 1.03 0.82 
Cu 2.32 1.41 0.17 0.65 0.95 
Pb  2.04 1.09 1.51 1.05 
Al 2.5 2.04 0.93 1.24 0.94 
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Figure 8.  Graph Summarizing % Moisture by Karl Fischer for Lyophilization Runs 
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 The assay testing was used to demonstrate that the lyophilization cycle did not cause loss 
of the diclofenac salt during the cycle.  The stock solutions and reconstituted lyophilization 
samples were analyzed by UV for diclofenac content.  Analysis of both the stock solution and 
the reconstituted samples demonstrated that the lyophilization cycle did not cause any loss in 
diclofenac concentration. 
Conclusions 
        Several non-commercially available diclofenac salts were successfully prepared and 
characterized using standard laboratory testing including purity assay, melting point, crystallinity 
determination, TGA, DSC, solubility in water and pH buffers 4, 7, 8, and 10.  The solubility data 
demonstrated that the diclofenac salts solubility was pH dependent with a higher solubility at pH 
10 versus pH 4.   The data suggests the solubility of the diclofenac salts may decrease as the size 
of the cation increases in each of the valence categories, however statistical interpretation of the 
data using regression analysis showed no trends among each of the different cations (P<0.05).  
Ionic strength also plays a strong role in solubility.   Of the +2 cations, the copper salt did show a 
slightly higher solubility versus the other +2 cations.   The copper has two different crystalline 
forms and one could have a much larger solubility and skew the results.  The different crystalline 
structures of copper diclofenac could be separated and individually characterized to provide 
more a comprehensive solubility curve.   A correlation could not be derived from the solubility 
of the sodium, magnesium, and aluminum cations, in that their atomic numbers are in sequence 
and they represent + 1, +2 and +3 cations.  Statistical analysis demonstrated that there were no 
trends in the solubility data other than solubility generally decreased as atomic number 
increased.  Atomic radii did not affect the solubility in any of the experiments.  Statistical 
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analysis of the solubility results when compared to the atomic radii showed no trends at a 
confidence level of greater that 90%. 
 A lyophilization cycle was established over a series of experiments until minimum 
lyophilization cake criteria were met.  The lyophilization cake minimum criteria included a 
formed cake that did not melt back and a cake that had some basic tolerance for the process.  The 
cycle was then used to prepare lyophilization cake samples that could be directly compared to 
one another.  The experiments demonstrated that differences could be seen between the different 
salts of diclofenac in the earlier lyophilization runs.  There were differences in cake heights 
during the cycles with shorter primary drying times.  These differences were explained as cake 
melt back from residual water.  There were also differences noted in the residual moisture in the 
lyophilized cakes.  The percent moisture differences ranged from approximately 2.3% in short 
primary drying runs and decreased to less than 0.5% with the longest primary drying run.  It was 
noted that as the drying times were increased to achieve a pharmaceutically acceptable percent 
moisture, the differences in residual moisture were not as great.  The lyophilized cake 
appearances were consistent between all of the salts except for copper. All the cakes were white 
with a brittle crust and a floss like interior, the copper salts lyophilization cake was pale green in 
color with the same physical characteristics as the other cakes. All samples met the criteria for 
the USP test for clarity of solution.  All of the reconstituted solutions including the copper, were 
clear with no visible particulates visible.  
        This research demonstrated that the different salts of diclofenac do have an effect of the 
final lyophilization cake.  The lyophilized cake’s appearance, reconstitution time, percent 
moisture and primary drying time were all affected by the different salts of diclofenac.   
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        This data demonstrates that in choosing a new salt for a lyophilized product, solubility in 
the chosen solvent system will determine the final concentration of product in the vial.  Although 
this data did not demonstrate any overall increase in solubility due to a cation affect, the salts 
solubility profile was pH dependent.  Understanding the new salts solubility profile provides the 
correct information on predicting the maximum allowable concentration and therefore provides 
the first step in formulation of a new lyophilized product.  Understanding the physical 
characteristics of the salt can provide information on how the product will lyophilize.  Based on 
this research, a larger more defined crystal could decrease the primary drying time versus a 
smaller less defined crystalline salt.  It was hypothesized that the larger crystal provided 
channeling in the lyophilized cake, allowing for shorter primary drying times.   Lyophilization 
cycle development was shown to be dependent on the fill volume, bulking agent concentration, 
and the cakes ability to transmit moisture.  Defining the fill volume for a new salt would provide 
basic information on the amount of primary drying necessary to dry the product to an acceptable 
moisture level.  Using all of this information together provides a framework for formulation and 
development of a new lyophilized product. 
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Appendix A
 
Lyophilization Cycle Raw Data 
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Run 09-18-2005 16 Hours Primary Drying 
Rate °C/min 
Final 
Temperature 
°C 
Hold Time 
(minutes) 
Pressure MT 
Step 
Definitions 
0.2 -40 120 Ambient Freezing 
Evacuate the chamber 
Fore line Pressure = 135 mT 
Chamber Pressure = 185 mT 
0.1 -10 960 225 
Primary 
Drying 
0.1 27 720 225 
Secondary 
Drying 
0.0 27 NA 1100 Vial Sealing 
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Run 10-06-2005 24 Hours Primary Drying 
Rate °C/min 
Final 
Temperature 
°C 
Hold Time 
(minutes) 
Pressure MT 
Step 
Definitions 
0.2 -40 120 Ambient Freezing 
Evacuate the chamber 
Fore line Pressure = 135 mT 
Chamber Pressure = 185 mT 
0.1 -10 1440 225 
Primary 
Drying 
0.1 27 720 225 
Secondary 
Drying 
0.0 27 NA 1100 Vial Sealing 
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Run 10-16-2005 36 Hours Primary Drying 
Rate °C/min 
Final 
Temperature 
°C 
Hold Time 
(minutes) 
Pressure MT 
Step 
Definitions 
0.2 -40 120 Ambient Freezing 
Evacuate the chamber 
Fore line Pressure = 135 mT 
Chamber Pressure = 185 mT 
0.1 -10 2160 225 
Primary 
Drying 
0.1 27 720 225 
Secondary 
Drying 
0.0 27 NA 1100 Vial Sealing 
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Run 02-19-2006 48 Hours Primary Drying 
Rate °C/min 
Final 
Temperature 
°C 
Hold Time 
(minutes) 
Pressure MT 
Step 
Definitions 
0.2 -40 120 Ambient Freezing 
Evacuate the chamber 
Fore line Pressure = 135 mT 
Chamber Pressure = 185 mT 
0.1 -10 2880 225 
Primary 
Drying 
0.1 27 720 225 
Secondary 
Drying 
0.0 27 NA 1100 Vial Sealing 
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Run 04-03-2006 48 Hours Primary Drying 24 Hours Secondary Drying 
Rate °C/min 
Final 
Temperature 
°C 
Hold Time 
(minutes) 
Pressure MT 
Step 
Definitions 
0.2 -40 120 Ambient Freezing 
Evacuate the chamber 
Fore line Pressure = 135 mT 
Chamber Pressure = 185 mT 
0.1 -10 2880 225 
Primary 
Drying 
0.1 27 1440 225 
Secondary 
Drying 
0.0 27 NA 1100 Vial Sealing 
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Appendix B 
 
TGA Printouts 
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Appendix C 
 
Differential Scanning Calorimetry 
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Appendix D 
 
Diclofenac Salt Structures 
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Diclofenac Free Acid 
H
N
H2C
C
OH
O
Cl
Cl
C14H11Cl2NO2
Exact Mass: 295.02
Mol. Wt.: 296.15
C, 56.78; H, 3.74; Cl, 23.94; N, 4.73; O, 10.80  
 
Sodium Diclofenac 
H
N
H2C
C
O
O
Cl
Cl
Na
C14H10Cl2NNaO2
Exact Mass: 317.00
Mol. Wt.: 318.13
C, 52.86; H, 3.17; Cl, 22.29; N, 4.40; Na, 7.23; O, 10.06  
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Potassium Diclofenac 
H
N
H2C
C
O
O
Cl
Cl
K
C14H10Cl2KNO2
Exact Mass: 332.97
Mol. Wt.: 334.24
C, 50.31; H, 3.02; Cl, 21.21; K, 11.70; N, 4.19; O, 9.57  
 
Ammonium Diclofenac 
H
N
H2C
C
O
O
Cl
Cl
NH2
C15H16Cl2N2O2
Exact Mass: 326.06
Mol. Wt.: 327.21
C, 55.06; H, 4.93; Cl, 21.67; N, 8.56; O, 9.78  
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Magnesium Diclofenac 
H
N
H2C
C
O
O
Cl
Cl
Mg
H
N
CH2
C
O
O
Cl
Cl
C28H20Cl4MgN2O4
Exact Mass: 612.00
Mol. Wt.: 614.59
C, 54.72; H, 3.28; Cl, 23.07; Mg, 3.95; N, 4.56; O, 10.41  
 
Copper Diclofenac 
H
N
H2C
C
O
O
Cl
Cl
H
N
CH2
C
O
O
Cl
Cl
Cu
C28H20Cl4CuN2O4
Exact Mass: 650.96
Mol. Wt.: 653.83
C, 51.44; H, 3.08; Cl, 21.69; Cu, 9.72; N, 4.28; O, 9.79  
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Zinc Diclofenac 
H
N
H2C
C
O
O
Cl
Cl
H
N
CH2
C
O
O
Cl
Cl
Zn
C28H20Cl4N2O4Zn
Exact Mass: 651.95
Mol. Wt.: 655.67
C, 51.29; H, 3.07; Cl, 21.63; N, 4.27; O, 9.76; Zn, 9.97  
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Lead Diclofenac 
H
N
H2C
C
O
O
Cl
Cl
Pb
H
N
CH2
C
O
O
Cl
Cl
C28H20Cl4N2O4Pb
Exact Mass: 795.99
Mol. Wt.: 797.48
C, 42.17; H, 2.53; Cl, 17.78; N, 3.51; O, 8.02; Pb, 25.98  
 
 
 
 
 
 
 
 
 
 
 
Aluminum Diclofenac 
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HN
H2C
C
O O
Cl Cl
Al
H
N
H2C
C
O
O Cl
Cl
NH
C
H2
C
O
O
Cl Cl
C43H34AlCl6N3O6
Exact Mass: 925.04
Mol. Wt.: 928.44
C, 55.63; H, 3.69; Al, 2.91; Cl, 22.91; N, 4.53; O, 10.34  
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Appendix E 
 
X-Ray Diffraction Chromatography 
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